240 related articles for article (PubMed ID: 1497094)
1. Effect of serum amyloid P component level on transthyretin-derived amyloid deposition in a transgenic mouse model of familial amyloidotic polyneuropathy.
Murakami T; Yi S; Maeda S; Tashiro F; Yamamura K; Takahashi K; Shimada K; Araki S
Am J Pathol; 1992 Aug; 141(2):451-6. PubMed ID: 1497094
[TBL] [Abstract][Full Text] [Related]
2. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
Maeda S
Amyloid; 2003 Aug; 10 Suppl 1():17-20. PubMed ID: 14640037
[TBL] [Abstract][Full Text] [Related]
3. Transgenic mouse model of familial amyloidotic polyneuropathy.
Shimada K; Maeda S; Murakami T; Nishiguchi S; Tashiro F; Yi S; Wakasugi S; Takahashi K; Yamamura K
Mol Biol Med; 1989 Aug; 6(4):333-43. PubMed ID: 2560117
[TBL] [Abstract][Full Text] [Related]
4. Role of serum amyloid P component for systemic amyloidosis in transgenic mice carrying human mutant transthyretin gene.
Tashiro F; Yi S; Wakasugi S; Maeda S; Shimada K; Yamamura K
Gerontology; 1991; 37 Suppl 1():56-62. PubMed ID: 1937069
[TBL] [Abstract][Full Text] [Related]
5. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
Cardoso I; Saraiva MJ
FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795
[TBL] [Abstract][Full Text] [Related]
6. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I.
Yi S; Takahashi K; Naito M; Tashiro F; Wakasugi S; Maeda S; Shimada K; Yamamura K; Araki S
Am J Pathol; 1991 Feb; 138(2):403-12. PubMed ID: 1992765
[TBL] [Abstract][Full Text] [Related]
7. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M
Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615
[TBL] [Abstract][Full Text] [Related]
8. Aging and transthyretin-related amyloidosis: pathologic examinations in pulmonary amyloidosis.
Ueda M; Ando Y; Haraoka K; Katsuragi S; Terasaki Y; Sugimoto M; Sun X; Uchino M
Amyloid; 2006 Mar; 13(1):24-30. PubMed ID: 16690497
[TBL] [Abstract][Full Text] [Related]
9. Liver-specific and high-level expression of human serum amyloid P component gene in transgenic mice.
Iwanaga T; Wakasugi S; Inomoto T; Uehira M; Ohnishi S; Nishiguchi S; Araki K; Uno M; Miyazaki J; Maeda S
Dev Genet; 1989; 10(5):365-71. PubMed ID: 2598499
[TBL] [Abstract][Full Text] [Related]
10. [Amyloid neuropathy].
Ikegawa S
Rinsho Shinkeigaku; 1990 Dec; 30(12):1371-3. PubMed ID: 1966018
[TBL] [Abstract][Full Text] [Related]
11. Acute-phase reactants of mice. II. Strain dependence of serum amyloid P-component (SAP) levels and response to inflammation.
Mortensen RF; Beisel K; Zeleznik NJ; Le PT
J Immunol; 1983 Feb; 130(2):885-9. PubMed ID: 6600258
[TBL] [Abstract][Full Text] [Related]
12. In vivo stabilization of mutant human transthyretin in transgenic mice.
Tagoe CE; Reixach N; Friske L; Mustra D; French D; Gallo G; Buxbaum JN
Amyloid; 2007 Sep; 14(3):227-36. PubMed ID: 17701470
[TBL] [Abstract][Full Text] [Related]
13. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.
Baltz ML; Caspi D; Evans DJ; Rowe IF; Hind CR; Pepys MB
Clin Exp Immunol; 1986 Dec; 66(3):691-700. PubMed ID: 3568456
[TBL] [Abstract][Full Text] [Related]
14. Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met 30) gene. Pathological and immunohistochemical similarity to human familial amyloidotic polyneuropathy, type I.
Araki S; Yi S; Murakami T; Watanabe S; Ikegawa S; Takahashi K; Yamarnura K
Mol Neurobiol; 1994 Feb; 8(1):15-23. PubMed ID: 8086125
[TBL] [Abstract][Full Text] [Related]
15. Low plasma apolipoprotein AII levels in human and mouse amyloidosis with mutant transthyretin (Met-30) gene.
Ando Y; Tanaka Y; Ueyama H; Sakashita N; Yonehara T; Higuchi K; Araki S
Ann Neurol; 1993 Jan; 33(1):101-3. PubMed ID: 8494327
[TBL] [Abstract][Full Text] [Related]
16. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
Zhang Q; Kelly JW
Biochemistry; 2005 Jun; 44(25):9079-85. PubMed ID: 15966731
[TBL] [Abstract][Full Text] [Related]
17. Significant deposition of wild type transthyretin-derived amyloid in the gastrointestinal tract of aged individuals.
Ikeda S; Tojo K; Suzuki-Tsuchiya A; Akamatu T; Hashimoto T; Higuchi K
Amyloid; 2009; 16(3):174-7. PubMed ID: 19626481
[TBL] [Abstract][Full Text] [Related]
18. [Pathogenesis and therapy for transthyretin related amyloidosis].
Ando Y; Jono H
Rinsho Byori; 2008 Feb; 56(2):114-20. PubMed ID: 18402051
[TBL] [Abstract][Full Text] [Related]
19. Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met.
Dardiotis E; Koutsou P; Zamba-Papanicolaou E; Vonta I; Hadjivassiliou M; Hadjigeorgiou G; Cariolou M; Christodoulou K; Kyriakides T
J Neurol Sci; 2009 Sep; 284(1-2):158-62. PubMed ID: 19493541
[TBL] [Abstract][Full Text] [Related]
20. Modeling familial amyloidotic polyneuropathy (Transthyretin V30M) in Drosophila melanogaster.
Berg I; Thor S; Hammarström P
Neurodegener Dis; 2009; 6(3):127-38. PubMed ID: 19372706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
